NO330195B1 - Farmasoytisk aerosolsammensetning inneholdende HFA 227 og HFA 134a - Google Patents

Farmasoytisk aerosolsammensetning inneholdende HFA 227 og HFA 134a Download PDF

Info

Publication number: NO330195B1
Authority: NO; Norway
Prior art keywords: hfa; aerosol; propellant; composition; mmad
Prior art date: 1998-11-25

Application number

NO20012517A

Other languages

English (en)

Norwegian (no)

Other versions

NO20012517D0 (no

NO20012517L (no

Inventor

Paolo Ventura

David Lewis

David Ganderton

Brian John Meakin

Gaetano Brambilla

Raffaella Garzia

Original Assignee

Chiesi Farma Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-25

Filing date

2001-05-22

Publication date

2011-03-07

2001-05-22 Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa

2001-05-22 Publication of NO20012517D0 publication Critical patent/NO20012517D0/no

2001-07-23 Publication of NO20012517L publication Critical patent/NO20012517L/no

2011-03-07 Publication of NO330195B1 publication Critical patent/NO330195B1/no

Links

239000000203 mixture Substances 0.000 title claims abstract description 96
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 title claims abstract description 18
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 title claims abstract description 17
239000008249 pharmaceutical aerosol Substances 0.000 title description 4
239000000443 aerosol Substances 0.000 claims abstract description 45
239000003380 propellant Substances 0.000 claims abstract description 37
150000005828 hydrofluoroalkanes Chemical class 0.000 claims abstract description 18
239000011149 active material Substances 0.000 claims abstract description 14
239000006184 cosolvent Substances 0.000 claims abstract description 9
229940071648 metered dose inhaler Drugs 0.000 claims description 6
239000000812 cholinergic antagonist Substances 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 4
239000003246 corticosteroid Substances 0.000 claims description 4
229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 3
229940124748 beta 2 agonist Drugs 0.000 claims description 3
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
239000005642 Oleic acid Substances 0.000 claims description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
125000003158 alcohol group Chemical group 0.000 claims description 2
239000003245 coal Substances 0.000 claims description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
239000002245 particle Substances 0.000 abstract description 45
239000010419 fine particle Substances 0.000 abstract description 6
239000004480 active ingredient Substances 0.000 abstract description 5
150000001875 compounds Chemical class 0.000 abstract description 4
210000002345 respiratory system Anatomy 0.000 abstract description 4
238000009472 formulation Methods 0.000 description 36
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
229940079593 drug Drugs 0.000 description 17
239000003814 drug Substances 0.000 description 17
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
239000000725 suspension Substances 0.000 description 11
230000008021 deposition Effects 0.000 description 10
230000000694 effects Effects 0.000 description 9
239000004094 surface-active agent Substances 0.000 description 9
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 8
210000004072 lung Anatomy 0.000 description 8
239000000463 material Substances 0.000 description 7
239000002904 solvent Substances 0.000 description 7
230000004913 activation Effects 0.000 description 5
238000001994 activation Methods 0.000 description 5
238000009826 distribution Methods 0.000 description 5
MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 4
239000002270 dispersing agent Substances 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
238000004062 sedimentation Methods 0.000 description 4
150000003431 steroids Chemical class 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 3
235000019404 dichlorodifluoromethane Nutrition 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
238000006073 displacement reaction Methods 0.000 description 3
230000005484 gravity Effects 0.000 description 3
238000000034 method Methods 0.000 description 3
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 3
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000000556 agonist Substances 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
-1 antileukotrienes Substances 0.000 description 2
229950000210 beclometasone dipropionate Drugs 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000006260 foam Substances 0.000 description 2
150000002334 glycols Chemical class 0.000 description 2
NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
229940127557 pharmaceutical product Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 1
WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
230000005653 Brownian motion process Effects 0.000 description 1
239000004255 Butylated hydroxyanisole Substances 0.000 description 1
239000004322 Butylated hydroxytoluene Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
235000021360 Myristic acid Nutrition 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000002590 anti-leukotriene effect Effects 0.000 description 1
239000000043 antiallergic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
230000004097 bone metabolism Effects 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
238000005537 brownian motion Methods 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
229940043253 butylated hydroxyanisole Drugs 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
229940095259 butylated hydroxytoluene Drugs 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
238000010000 carbonizing Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
150000001840 cholesterol esters Chemical class 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
229960005233 cineole Drugs 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
238000002788 crimping Methods 0.000 description 1
239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
238000000227 grinding Methods 0.000 description 1
UKACHOXRXFQJFN-UHFFFAOYSA-N heptafluoropropane Chemical compound FC(F)C(F)(F)C(F)(F)F UKACHOXRXFQJFN-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000002664 inhalation therapy Methods 0.000 description 1
229960001361 ipratropium bromide Drugs 0.000 description 1
KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
239000001282 iso-butane Substances 0.000 description 1
239000000832 lactitol Substances 0.000 description 1
235000010448 lactitol Nutrition 0.000 description 1
VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
229960003451 lactitol Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
235000001510 limonene Nutrition 0.000 description 1
229940087305 limonene Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000845 maltitol Substances 0.000 description 1
235000010449 maltitol Nutrition 0.000 description 1
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
229940035436 maltitol Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229940041616 menthol Drugs 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
229940038384 octadecane Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
210000003300 oropharynx Anatomy 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
239000001294 propane Substances 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
235000007586 terpenes Nutrition 0.000 description 1
BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
229940042585 tocopherol acetate Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
150000005691 triesters Chemical class 0.000 description 1
239000003039 volatile agent Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
Dispersion Chemistry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20012517A 1998-11-25 2001-05-22 Farmasoytisk aerosolsammensetning inneholdende HFA 227 og HFA 134a NO330195B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IT1998MI002558A IT1303788B1 (it)	1998-11-25	1998-11-25	Formulazioni di aerosol medicinali.
PCT/EP1999/008959 WO2000030607A1 (en)	1998-11-25	1999-11-22	PHARMACEUTICAL AEROSOL COMPOSITION CONTAINING HFA 227 AND HFA 134a

Publications (3)

Publication Number	Publication Date
NO20012517D0 NO20012517D0 (no)	2001-05-22
NO20012517L NO20012517L (no)	2001-07-23
NO330195B1 true NO330195B1 (no)	2011-03-07

Family

ID=11381136

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20012517A NO330195B1 (no)	1998-11-25	2001-05-22	Farmasoytisk aerosolsammensetning inneholdende HFA 227 og HFA 134a

Country Status (22)

Country	Link
US (2)	US6713047B1 (de)
EP (1)	EP1133277B1 (de)
JP (1)	JP2002530316A (de)
KR (1)	KR100794060B1 (de)
CN (1)	CN1177582C (de)
AT (1)	ATE368450T1 (de)
AU (1)	AU770529B2 (de)
BR (1)	BR9916865A (de)
CA (1)	CA2352483C (de)
CY (1)	CY1106904T1 (de)
DE (1)	DE69936730T2 (de)
DK (1)	DK1133277T3 (de)
ES (1)	ES2289832T3 (de)
IL (1)	IL143293A0 (de)
IT (1)	IT1303788B1 (de)
MA (1)	MA26763A1 (de)
NO (1)	NO330195B1 (de)
NZ (1)	NZ511923A (de)
PT (1)	PT1133277E (de)
TR (1)	TR200101442T2 (de)
WO (1)	WO2000030607A1 (de)
ZA (1)	ZA200104220B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010031244A1 (en) *	1997-06-13	2001-10-18	Chiesi Farmaceutici S.P.A.	Pharmaceutical aerosol composition
DZ2947A1 (fr) *	1998-11-25	2004-03-15	Chiesi Farma Spa	Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) *	1998-11-25	2001-02-23	Chiesi Farma Spa	Formulazioni di aerosol medicinali.
US6739333B1 (en)	1999-05-26	2004-05-25	Boehringer Ingelheim Pharma Kg	Stainless steel canister for propellant-driven metering aerosols
US6315985B1 (en) *	1999-06-18	2001-11-13	3M Innovative Properties Company	C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (it)	1999-07-23	2002-09-09	Chiesi Farma Spa	Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
AU7026800A (en)	1999-09-11	2001-04-17	Glaxo Group Limited	Pharmaceutical formulation of fluticasone propionate
ES2238334T3 (es) *	1999-12-24	2005-09-01	Glaxo Group Limited	Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona.
IT1317720B1 (it) *	2000-01-07	2003-07-15	Chiesi Farma Spa	Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) *	2000-05-12	2003-08-27	Chiesi Farma Spa	Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
JP5392880B2 (ja) *	2000-05-22	2014-01-22	キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ	加圧式定量吸入器のための安定な製薬学的溶液製剤
US20060257324A1 (en)	2000-05-22	2006-11-16	Chiesi Farmaceutici S.P.A.	Pharmaceutical solution formulations for pressurised metered dose inhalers
GB2367011A (en) *	2000-08-26	2002-03-27	Glaxo Group Ltd	Metered dose inhaler for salmeterol
ES2222294T3 (es) *	2001-07-02	2005-02-01	Chiesi Farmaceutici S.P.A.	Formulacion optimizada de tobramicina para administracion en forma de aerosol.
EP1340503A1 (de) *	2002-03-01	2003-09-03	CHIESI FARMACEUTICI S.p.A.	Lösung Aerosol Formulierung von Estern von 3,17-dihydroxy Oestratrien-Derivaten zur Lungenverabreichung
EP1340492A1 (de) *	2002-03-01	2003-09-03	CHIESI FARMACEUTICI S.p.A.	Aerosolformulierungen zur pulmonalen Verabreichung von Arzneimitteln mit systemischer Wirkung
EP3384931B1 (de) *	2002-03-01	2019-07-24	Chiesi Farmaceutici S.p.A.	Superfeine salmeterol zubereitung
EP1415647A1 (de) *	2002-10-23	2004-05-06	CHIESI FARMACEUTICI S.p.A.	Langwirkende beta-2-Agonisten in ultrafeiner Formulierung
US7311894B2 (en)	2002-03-28	2007-12-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	HFA suspension formulations containing an anticholinergic
EP1369113B1 (de) *	2002-06-06	2006-11-22	CHIESI FARMACEUTICI S.p.A.	Lösung von Wirkstoffen in HFA-Treibgasen mittels Emulsionen
EP1452179A1 (de) *	2003-02-27	2004-09-01	CHIESI FARMACEUTICI S.p.A.	Neue Kombination von hochwirksamer langzeitiger Beta-2-Agonist und einem Corticosteroid
EP1915985A1 (de)	2003-03-20	2008-04-30	Boehringer Ingelheim Pharmaceuticals Inc.	Formulierung für einen Dosierinhalator mit Hydrofluoralkanen als Treibstoffen
WO2004084858A2 (en)	2003-03-20	2004-10-07	Boehringer Ingelheim Pharmaceuticals, Inc.	Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants
RU2364400C2 (ru) *	2003-04-14	2009-08-20	Вектура Лтд	Фармацевтические композиции
CA2538237A1 (en) *	2003-09-10	2005-03-24	Map Pharmaceuticals, Inc.	Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
AR041873A1 (es) *	2003-10-30	2005-06-01	Pablo Cassara Srl Lab	Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
SE0303179D0 (sv) *	2003-11-26	2003-11-26	Astrazeneca Ab	Novel compounds
KR20070000476A (ko) *	2004-02-27	2007-01-02	키에시 파르마슈티시 엣스. 피. 에이.	압축화 계량된 도스흡입용 안정된 약제용액 제제
EP1595531A1 (de) *	2004-05-13	2005-11-16	CHIESI FARMACEUTICI S.p.A.	Stabile Arzneimittellösung für Druckdosierinhalatoren
CN1583170A (zh) *	2004-06-10	2005-02-23	安米	用于抗病毒抗耐药菌的人溶菌酶药物及其制法
NZ552869A (en)	2004-07-02	2010-06-25	Boehringer Ingelheim Int	Aerosol suspension formulations containing TG 227 ea as a propellant, an ipratropium or tiotropium salt and a small amount of free water to stabilise the composition
DE102006017320A1 (de)	2006-04-11	2007-10-18	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
EP2011534A1 (de) *	2007-07-03	2009-01-07	CHIESI FARMACEUTICI S.p.A.	Aktuator für einen Inhalator für abgemessene Dosen
WO2011150441A1 (en) *	2010-06-03	2011-12-08	Wholesome Biopharm Pty Ltd	Medical aerosol formulation comprising ribavirin
CA2807406C (en) *	2010-08-03	2018-12-11	Chiesi Farmaceutici S.P.A.	Pharmaceutical formulation comprising a phosphodiesterase inhibitor
US20140377189A1 (en) *	2013-06-19	2014-12-25	Map Pharmaceuticals, Inc.	Pulmonary administration of rotigotine
US20160310410A1 (en)	2015-04-24	2016-10-27	Glenmark Specialty S.A.	Pharmaceutical compositions comprising arformoterol and glycopyrronium
CN114796166A (zh) *	2021-01-29	2022-07-29	北京远大九和药业有限公司	一种含有萜烯类挥发油的气雾剂及其制备方法
CN114522143B (zh) *	2022-02-22	2026-02-06	暨南大学	用于吸入气雾剂的低制冷效应复合抛射剂及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH89518A (de) *	1919-03-22	1921-06-01	Croning Johannes	Der Türdicke entsprechend einstellbares Gehäuse für Zylinderschlösser.
US3095355A (en) *	1961-10-12	1963-06-25	Revlon	Aerosol composition
US3860618A (en) *	1967-08-08	1975-01-14	Philip Saxton Hartley	Chromone
US5192528A (en) *	1985-05-22	1993-03-09	Liposome Technology, Inc.	Corticosteroid inhalation treatment method
GB8828477D0 (en) *	1988-12-06	1989-01-05	Riker Laboratories Inc	Medical aerosol formulations
MX9203481A (es) *	1990-10-18	1992-07-01	Minnesota Mining & Mfg	Formulaciones.
JP2769925B2 (ja)	1990-10-18	1998-06-25	ミネソタマイニングアンドマニュファクチャリングカンパニー	ベクロメタゾン１７，２１ジプロピオネートを含んで成るエアロゾル製剤
US5190029A (en) *	1991-02-14	1993-03-02	Virginia Commonwealth University	Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5653961A (en) *	1995-03-31	1997-08-05	Minnesota Mining And Manufacturing Company	Butixocort aerosol formulations in hydrofluorocarbon propellant
AP791A (en) *	1995-04-14	1999-12-17	Glaxo Wellcome Inc	Metered dose inhaler for albuterol.
GB9612297D0 (en) *	1996-06-11	1996-08-14	Minnesota Mining & Mfg	Medicinal aerosol formulations
WO1998001147A1 (en) *	1996-07-08	1998-01-15	Rhone-Poulenc Rorer Limited	Medicinal cyclosporin-a aerosol solution formulation
GB9620187D0 (en) *	1996-09-27	1996-11-13	Minnesota Mining & Mfg	Medicinal aerosol formulations
AU718967B2 (en) *	1997-02-05	2000-05-04	Jagotec Ag	Medical aerosol formulations
US6126919A (en) *	1997-02-07	2000-10-03	3M Innovative Properties Company	Biocompatible compounds for pharmaceutical drug delivery systems
GB2326334A (en) *	1997-06-13	1998-12-23	Chiesi Farma Spa	Pharmaceutical aerosol compositions
IT1303788B1 (it) *	1998-11-25	2001-02-23	Chiesi Farma Spa	Formulazioni di aerosol medicinali.
US6004537A (en)	1998-12-18	1999-12-21	Baker Norton Pharmaceuticals, Inc.	Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
JP5392880B2 (ja) *	2000-05-22	2014-01-22	キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ	加圧式定量吸入器のための安定な製薬学的溶液製剤
EP1415647A1 (de) *	2002-10-23	2004-05-06	CHIESI FARMACEUTICI S.p.A.	Langwirkende beta-2-Agonisten in ultrafeiner Formulierung
EP1340492A1 (de) *	2002-03-01	2003-09-03	CHIESI FARMACEUTICI S.p.A.	Aerosolformulierungen zur pulmonalen Verabreichung von Arzneimitteln mit systemischer Wirkung
EP3384931B1 (de) *	2002-03-01	2019-07-24	Chiesi Farmaceutici S.p.A.	Superfeine salmeterol zubereitung

1998
- 1998-11-25 IT IT1998MI002558A patent/IT1303788B1/it active
1999
- 1999-11-22 CN CNB998148717A patent/CN1177582C/zh not_active Expired - Fee Related
- 1999-11-22 BR BR9916865-0A patent/BR9916865A/pt not_active Application Discontinuation
- 1999-11-22 ES ES99958096T patent/ES2289832T3/es not_active Expired - Lifetime
- 1999-11-22 KR KR1020017006520A patent/KR100794060B1/ko not_active Expired - Fee Related
- 1999-11-22 WO PCT/EP1999/008959 patent/WO2000030607A1/en not_active Ceased
- 1999-11-22 JP JP2000583491A patent/JP2002530316A/ja active Pending
- 1999-11-22 US US09/831,886 patent/US6713047B1/en not_active Expired - Fee Related
- 1999-11-22 AT AT99958096T patent/ATE368450T1/de active
- 1999-11-22 PT PT99958096T patent/PT1133277E/pt unknown
- 1999-11-22 AU AU15553/00A patent/AU770529B2/en not_active Ceased
- 1999-11-22 NZ NZ511923A patent/NZ511923A/en not_active IP Right Cessation
- 1999-11-22 TR TR2001/01442T patent/TR200101442T2/xx unknown
- 1999-11-22 EP EP99958096A patent/EP1133277B1/de not_active Expired - Lifetime
- 1999-11-22 DK DK99958096T patent/DK1133277T3/da active
- 1999-11-22 IL IL14329399A patent/IL143293A0/xx not_active IP Right Cessation
- 1999-11-22 CA CA002352483A patent/CA2352483C/en not_active Expired - Fee Related
- 1999-11-22 DE DE69936730T patent/DE69936730T2/de not_active Expired - Lifetime
2001
- 2001-05-22 MA MA26203A patent/MA26763A1/fr unknown
- 2001-05-22 NO NO20012517A patent/NO330195B1/no not_active IP Right Cessation
- 2001-05-23 ZA ZA200104220A patent/ZA200104220B/en unknown
2004
- 2004-01-30 US US10/766,857 patent/US20040184993A1/en not_active Abandoned
2007
- 2007-10-04 CY CY20071101264T patent/CY1106904T1/el unknown

Also Published As

Publication number	Publication date
KR20010080560A (ko)	2001-08-22
TR200101442T2 (tr)	2002-05-21
NO20012517D0 (no)	2001-05-22
AU770529B2 (en)	2004-02-26
DK1133277T3 (da)	2007-12-27
ATE368450T1 (de)	2007-08-15
MA26763A1 (fr)	2004-12-20
CN1331581A (zh)	2002-01-16
ITMI982558A1 (it)	2000-05-25
ZA200104220B (en)	2002-05-23
CA2352483A1 (en)	2000-06-02
ES2289832T3 (es)	2008-02-01
JP2002530316A (ja)	2002-09-17
CA2352483C (en)	2009-01-20
EP1133277A1 (de)	2001-09-19
CY1106904T1 (el)	2012-05-23
US6713047B1 (en)	2004-03-30
PT1133277E (pt)	2007-10-09
NZ511923A (en)	2003-10-31
DE69936730T2 (de)	2008-04-30
CN1177582C (zh)	2004-12-01
AU1555300A (en)	2000-06-13
US20040184993A1 (en)	2004-09-23
NO20012517L (no)	2001-07-23
EP1133277B1 (de)	2007-08-01
IT1303788B1 (it)	2001-02-23
DE69936730D1 (de)	2007-09-13
BR9916865A (pt)	2001-11-13
IL143293A0 (en)	2002-04-21
WO2000030607A1 (en)	2000-06-02
WO2000030607A8 (en)	2001-03-22
KR100794060B1 (ko)	2008-01-10

Legal Events

Date	Code	Title	Description
2014-06-23	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO330195B1 (no)	2011-03-07	Farmasoytisk aerosolsammensetning inneholdende HFA 227 og HFA 134a
EP0920302B1 (de)	2002-08-28	Pharmazeutische aerosolzusammensetzung
US8420058B2 (en)	2013-04-16	Pharmaceutical aerosol composition
AU774250B2 (en)	2004-06-24	Pharmaceutical aerosol composition